Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer.
Huang AC, Huang CH, Ju JS, Chiu TH, Tung PH, Wang CC, Liu CY, Chung FT, Fang YF, Guo YK, Kuo CS, Yang CT. Huang AC, et al. Among authors: ju js. Ther Adv Med Oncol. 2021 Jul 31;13:17588359211035710. doi: 10.1177/17588359211035710. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34377157 Free PMC article.
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study.
Lee SH, Lin YC, Chiu LC, Ju JS, Tung PH, Huang AC, Li SH, Fang YF, Chen CH, Kuo SC, Wang CC, Yang CT, Hsu PC. Lee SH, et al. Among authors: ju js. Ther Adv Med Oncol. 2022 Jul 23;14:17588359221113278. doi: 10.1177/17588359221113278. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35898964 Free PMC article.
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.
Hsu PC, Huang CY, Lin YC, Lee SH, Chiu LC, Wu CE, Kuo SC, Ju JS, Huang AC, Ko HW, Wang CC, Yang CT. Hsu PC, et al. Among authors: ju js. Front Oncol. 2023 Oct 3;13:1249106. doi: 10.3389/fonc.2023.1249106. eCollection 2023. Front Oncol. 2023. PMID: 37854677 Free PMC article.
99 results